Company / FCF Margin
Arbutus Biopharma Corp FCF Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-281.4%
FY2025
5-year range
-1053.8% / -91.9%
FY2021-FY2025
Trend
+73.3%
vs FY2024
Sector context
#104 of 134
Health Care
What the data says
Arbutus Biopharma Corp's fcf margin of -281.4% is lower than 78% of companies in the Health Care sector (FY2025). FCF Margin returned to growth in FY2025 after 2 years of decline, reaching -281.4%.
Based on SEC 10-K filings.
-281.4% in FY2025 with a 5-year CAGR of +909.6%.
Improved from -479.3% to -281.4% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -189.5pp
- 5-Year Change
- +909.6pp
- 10-Year Change
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 134This company -281.4% Sector average -637.8%
▼
+55.9% above sector average
Key checks
Key Insights
- In FY2025, fcf margin increased 73.3% year-over-year.
- Currently 356.3pp above the Health Care sector average.
- Peak fcf margin was recorded in FY2022.
- Lowest fcf margin in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -281.4% | +73.3% |
| FY2024 | -1053.8% | -119.9% |
| FY2023 | -479.3% | -421.4% |
| FY2022 | -91.9% | +85.2% |
| FY2021 | -622.0% | +47.8% |
| FY2020 | -1191.1% | +72.6% |
| FY2019 | -4348.1% | -732.2% |
| FY2018 | -522.5% | +0.0% |
| FY2017 | -522.5% | +87.4% |
| FY2016 | -4150.3% | -1546.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026